Mr. Stephen Van Deventer reports

PREVECEUTICAL ANNOUNCES CANADIAN PATENT OFFICE ALLOWANCE OF INNOVATIVE PAIN THERAPY TECHNOLOGY

The Canadian Patent Office has allowed Canadian patent application No. 3127020, titled "A Cyclic Peptide", which relates to Preveceutical Medical Inc.'s pain therapy program. This allowance represents a significant milestone in the protection of Preveceutical's proprietary technologies aimed at addressing unmet needs in pain management.

The Canadian patent application is directed at novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse effects commonly associated with traditional opioid therapies, such as dependence and tolerance. The invention also encompasses pharmaceutical compositions and methods of use for treating or preventing pain in subjects, reinforcing the therapeutic potential of this technology.

This patent application is jointly owned by Preveceutical Medical and the University of Queensland, reflecting the strength of the collaborative research partnership between the two organizations. Grant of the application is expected in Q2 2026; the granted patent will provide exclusivity in Canada until January, 2040, subject to maintenance, and forms part of a broader patent family with corresponding applications pending in the United States, Europe and Australia. This global strategy ensures robust protection for Preveceutical's intellectual property portfolio and supports its long-term commercialization objectives.

Preveceutical's pain therapy program focuses on developing next-generation peptide-based analgesics that aim to overcome the limitations of conventional opioids. By leveraging advanced peptide engineering and cyclization techniques, these candidates are designed to exhibit enhanced stability and receptor selectivity, which could significantly improve patient outcomes in managing acute and chronic pain.

Preveceutical's chief executive officer, Stephen Van Deventer, commented: "The approval of this application is a significant milestone for Preveceutical, reaffirming our commitment to pioneering next-generation solutions in pain management. This intellectual property bolsters our position in a global market demanding safer alternatives to opioids and supports our long-term path to commercialization."

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.